Corrigendum to “Autophosphorylation in the Leucine-Rich Repeat Kinase 2 (LRRK2) GTPase Domain Modified Kinase and GTP-binding Activities” [J. Mol. Biol. 412(1) (2011) 94–110] (Autophosphorylation in the Leucine-Rich Repeat Kinase 2 (LRRK2) GTPase Domain Modifies Kinase and GTP-Binding Activities (2011) 412(1) (94–110), (S0022283611007984), (10.1016/j.jmb.2011.07.033));Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities

Journal of Molecular Biology

Volumn 412, Issue 1, 2011, Pages 94-110

  Webber, Philip J ^a,b   Smith, Archer D ^c,d,e   Sen, Saurabh ^a,b   Renfrow, Matthew B ^d,e   Mobley, James A ^c,d,e   West, Andrew B ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Kentucky   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

dardarin; neurodegeneration; PARK8; Parkinson disease; serine threonine kinase

Indexed keywords

ALANINE; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; LEUCINE RICH REPEAT KINASE 2; MYELIN BASIC PROTEIN; PHOSPHOTRANSFERASE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; CONTROLLED STUDY; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME BINDING; ENZYME SPECIFICITY; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION;

MUS MUSCULUS;

EID: 84860389765     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2021.167129     Document Type: Erratum

References (39)

1. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., and van der Brug M. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 2004 595 600 (Pubitemid 39531224)
2. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., and Lincoln S. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 2004 601 607 (Pubitemid 39531225)
3. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., and Dikeman D. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity Hum. Mol. Genet. 16 2007 223 232 (Pubitemid 46179004)
4. Webber P.J., and West A.B. LRRK2 in Parkinson's disease: function in cells and neurodegeneration FEBS J. 276 2009 6436 6444
5. Biskup S., Moore D.J., Rea A., Lorenz-Deperieux B., Coombes C.E., and Dawson V.L. Dynamic and redundant regulation of LRRK2 and LRRK1 expression BMC Neurosci. 8 2007 102
6. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., and Andrabi S.A. Localization of LRRK2 to membranous and vesicular structures in mammalian brain Ann. Neurol. 60 2006 557 569 (Pubitemid 44871798)
7. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., and Faull R.L. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain Brain Res. 1155 2007 208 219 (Pubitemid 46900930)
8. Gehrke S., Imai Y., Sokol N., and Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression Nature 466 2010 637 641
9. Carballo-Carbajal I., Weber-Endress S., Rovelli G., Chan D., Wolozin B., and Klein C.L. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway Cell Signalling 22 2010 821 827
10. Gloeckner C.J., Schumacher A., Boldt K., and Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro J. Neurochem. 109 2009 959 968
11. Hsu C.H., Chan D., and Wolozin B. LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins Neurodegener. Dis. 7 2010 68 75
12. Liou A.K., Leak R.K., Li L., and Zigmond M.J. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway Neurobiol. Dis. 32 2008 116 124
13. White L.R., Toft M., Kvam S.N., Farrer M.J., and Aasly J.O. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease J. Neurosci. Res. 85 2007 1288 1294 (Pubitemid 46724372)
14. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.L., and Long C.X. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis J. Neurosci. 29 2009 13971 13980
15. Anand V.S., Reichling L.J., Lipinski K., Stochaj W., Duan W., and Kelleher K. Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays FEBS J. 276 2009 466 478
16. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., and Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity Biochem. J. 405 2007 307 317 (Pubitemid 47075166)
17. Luzon-Toro B., Rubio de la Torre E., Delgado A., Perez-Tur J., and Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation Hum. Mol. Genet. 16 2007 2031 2039 (Pubitemid 47354886)
18. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., and Ross C.A. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl Acad. Sci. USA 102 2005 16842 16847 (Pubitemid 41688864)
19. Shohat G., Spivak-Kroizman T., Cohen O., Bialik S., Shani G., and Berrisi H. The pro-apoptotic function of death-associated protein kinase is controlled by a unique inhibitory autophosphorylation-based mechanism J. Biol. Chem. 276 2001 47460 47467
20. Kamikawaji S., Ito G., and Iwatsubo T. Identification of the autophosphorylation sites of LRRK2 Biochemistry 48 2009 10963 10975
21. Gloeckner C.J., Boldt K., von Zweydorf F., Helm S., Wiesent L., Sarioglu H., and Ueffing M. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2 J. Proteome Res. 9 2010 1738 1745
22. Greggio E., Taymans J.M., Zhen E.Y., Ryder J., Vancraenenbroeck R., and Beilina A. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites Biochem. Biophys. Res. Commun. 389 2009 449 454
23. Ito G., Okai T., Fujino G., Takeda K., Ichijo H., Katada T., and Iwatsubo T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease Biochemistry 46 2007 1380 1388 (Pubitemid 46208485)
24. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., and Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 9 2006 1231 1233 (Pubitemid 44454261)
25. Sen S., Webber P.J., and West A.B. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization J. Biol. Chem. 284 2009 36346 36356
26. Erickson A.K., Payne D.M., Martino P.A., Rossomando A.J., Shabanowitz J., and Weber M.J. Identification by mass spectrometry of threonine 97 in bovine myelin basic protein as a specific phosphorylation site for mitogen-activated protein kinase J. Biol. Chem. 265 1990 19728 19735 (Pubitemid 120013923)
27. Hirschberg D., Radmark O., Jornvall H., and Bergman T. Thr94 in bovine myelin basic protein is a second phosphorylation site for 42-kDa mitogen-activated protein kinase (ERK2) J. Protein Chem. 22 2003 177 181 (Pubitemid 38115214)
28. Kishimoto A., Nishiyama K., Nakanishi H., Uratsuji Y., Nomura H., Takeyama Y., and Nishizuka Y. Studies on the phosphorylation of myelin basic protein by protein kinase C and adenosine 3′:5′-monophosphate- dependent protein kinase J. Biol. Chem. 260 1985 12492 12499 (Pubitemid 16233449)
29. Martenson R.E., Law M.J., and Deibler G.E. Identification of multiple in vivo phosphorylation sites in rabbit myelin basic protein J. Biol. Chem. 258 1983 930 937 (Pubitemid 13139340)
30. Yu J.S., and Yang S.D. Protein kinase FA/glycogen synthase kinase-3 predominantly phosphorylates the in vivo site Thr97-Pro in brain myelin basic protein: evidence for Thr-Pro and Ser-Arg-X-X-Ser as consensus sequence motifs J. Neurochem. 62 1994 1596 1603
31. Chi A., Huttenhower C., Geer L.Y., Coon J.J., Syka J.E., and Bai D.L. Analysis of phosphorylation sites on proteins from Saccharomyces cerevisiae by electron transfer dissociation (ETD) mass spectrometry Proc. Natl Acad. Sci. USA 104 2007 2193 2198 (Pubitemid 46391374)
32. Nichols R.J., Dzamko N., Hutti J.E., Cantley L.C., Deak M., and Moran J. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease Biochem. J. 424 2009 47 60
33. Waxman E.A., Covy J.P., Bukh I., Li X., Dawson T.M., and Giasson B.I. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions J. Neuropathol. Exp. Neurol. 68 2009 785 796
34. Bourne H.R., Sanders D.A., and McCormick F. The GTPase superfamily: conserved structure and molecular mechanism Nature 349 1991 117 127 (Pubitemid 21912023)
35. Stokoe D., Macdonald S.G., Cadwallader K., Symons M., and Hancock J.F. Activation of Raf as a result of recruitment to the plasma membrane Science 264 1994 1463 1467 (Pubitemid 24217138)
36. Lewis P.A., Greggio E., Beilina A., Jain S., Baker A., and Cookson M.R. The R1441C mutation of LRRK2 disrupts GTP hydrolysis Biochem. Biophys. Res. Commun. 357 2007 668 671 (Pubitemid 46653831)
37. Li Y., Dunn L., Greggio E., Krumm B., Jackson G.S., and Cookson M.R. The R1441C mutation alters the folding properties of the ROC domain of LRRK2 Biochim. Biophys. Acta 1792 2009 1194 1197
38. Sweatt J.D., Atkins C.M., Johnson J., English J.D., Roberson E.D., and Chen S.J. Protected-site phosphorylation of protein kinase C in hippocampal long-term potentiation J. Neurochem. 71 1998 1075 1085 (Pubitemid 28390261)
39. Sen S., and West A.B. The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease Antioxid. Redox Signal. 11 2009 2167 2187